Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research firms also recently weighed in on AGIO. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. HC Wainwright raised their price target on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $57.00 to $28.00 in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Finally, Citigroup raised their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $40.67.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $27.85 on Friday. The stock has a market cap of $1.63 billion, a PE ratio of -3.92 and a beta of 0.89. The stock has a 50-day moving average of $28.14 and a two-hundred day moving average of $32.94. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Insider Activity at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 18,703 shares of the company’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the sale, the chief executive officer directly owned 136,583 shares of the company’s stock, valued at $3,700,033.47. This represents a 12.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider owned 5,141 shares in the company, valued at $142,919.80. The trade was a 36.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,262 shares of company stock worth $984,237 in the last ninety days. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $25,000. First Horizon Corp acquired a new stake in Agios Pharmaceuticals during the third quarter worth about $45,000. Assetmark Inc. raised its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 362 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals during the first quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.